Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAX phase II trial in recurrent or metastatic oesophago-gastric cancer
ACTRN12606000163505Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jun 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, cisplatin, fluorouracil and capecitabine in oesophago-gastric cancer (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Tumor response rate. Started Jun 2006; status: completed.
02
Drugs
docetaxelcisplatinfluorouracilcapecitabine
03
Conditions
oesophago-gastric cancer
Beyond the preview
Go deeper on ACTRN12606000163505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000163505.